Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines

Simple item page
dc.contributor.authorBartsch, Yannic C.
dc.contributor.authorTong, Xin
dc.contributor.authorKang, Jaewon
dc.contributor.authorAvendano, Maria Jose
dc.contributor.authorSerrano, Eileen F.
dc.contributor.authorGarcia-Salum, Tamara
dc.contributor.authorPardo-Roa, Catalina
dc.contributor.authorRiquelme, Arnoldo
dc.contributor.authorCai, Yongfei
dc.contributor.authorRenzi, Isabella
dc.contributor.authorStewart-Jones, Guillaume
dc.contributor.authorChen, Bing
dc.contributor.authorMedina, Rafael A.
dc.contributor.authorAlter, Galit
dc.date.accessioned2024-01-31T14:30:06Z
dc.date.available2024-01-31T14:30:06Z
dc.date.issued2022
dc.description.abstractThe Omicron variant of SARS-CoV-2 has been shown to evade neutralizing antibodies elicited by vaccination or infection. Despite the global spread of the Omicron variant, even among highly vaccinated populations, death rates have not increased concomitantly. These data suggest that immune mechanisms beyond antibody-mediated virus neutralization may protect against severe disease. In addition to neutralizing pathogens, antibodies contribute to control and clearance of infections through Fc effector mechanisms. Here, we probed the ability of vaccine-induced antibodies to drive Fc effector activity against the Omicron variant using samples from individuals receiving one of three SARS-CoV-2 vaccines. Despite a substantial loss of IgM, IgA, and IgG binding to the Omicron variant receptor binding domain (RBD) in samples from individuals receiving BNT162b2, mRNA-1273, and CoronaVac vaccines, stable binding was maintained against the full-length Omicron Spike protein. Compromised RBD binding IgG was accompanied by a loss of RBD-specific antibody Fc gamma receptor (Fe gamma R) binding in samples from individuals who received the CoronaVac vaccine, but RBD-specific Fc gamma R2a and Fc gamma R3a binding was preserved in recipients of mRNA vaccines. Conversely, Spike protein-specific antibodies exhibited persistent but reduced binding to Fc gamma Rs across all three vaccines, although higher binding was observed in samples from recipients of mRNA vaccines. This was associated with preservation of Fc gamma R2a and Fc gamma R3a binding antibodies and maintenance of Spike protein-specific antibody-dependent natural killer cell activation. Thus, despite the loss of Omicron neutralization, vaccine-induced Spike protein-specific antibodies continue to drive Fc effector functions, suggesting a capacity for extraneutralizing antibodies to contribute to disease control.
dc.description.funderSwiss National Centre of Competence in Research LIVES -Overcoming Vulnerability: Life Course Perspectives
dc.description.funderSwiss National Science Foundation (SNSF)
dc.description.funderNORFACE DIAL programme
dc.description.funderAgencia Nacional de Investigacion y Desarrollo (ANID), Chile
dc.format.extent30 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1126/scitranslmed.abn9243
dc.identifier.eissn1946-6242
dc.identifier.issn1946-6234
dc.identifier.scopusidSCOPUS_ID:85086945586
dc.identifier.urihttps://doi.org/10.1126/scitranslmed.abn9243
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/81120
dc.identifier.wosidWOS:000789484400005
dc.information.autorucFacultad de Medicina; Pardo Roa, Catalina; S/I; 225251
dc.issue.numero642
dc.language.isoen
dc.nota.accesoSin adjunto
dc.pagina.final95
dc.pagina.inicio71
dc.relation.ispartofWorld Congress of Cardiology, MAY 18-21, 2008, Buenos Aires, ARGENTINA
dc.revistaAGEING & SOCIETY
dc.rightsregistro bibliográfico
dc.subjectCOVID-19
dc.subjectSerological response
dc.subjectNeutralizing antibody persistence
dc.subjectSARS-CoV-2 vaccines
dc.subjectVaccination boost
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleOmicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines
dc.typeartículo
dc.volumen14
sipa.codpersvinculados225251
sipa.indexWOS
sipa.trazabilidadCarga SIPA;31-01-2024
Files
Collections
Artículos de revistas